GlassScriptPhysician profile
David Henry Perlmutter
NPI 1033420260
$35,584.49
in general payments reported to CMS, 2019-2025
43 companies · $3,835 in 2025
The $3,835 reported for 2025 was more than what 92% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,278 · 2020: $8,549 · 2021: $6,989 · 2022: $4,609 · 2023: $4,129 · 2024: $5,196 · 2025: $3,835.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,796 · Education: $43.51.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,320.68 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,795.88 |
| Education | $43.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $18,465.06 | 2019-2025 | Eylea Hd, Eylea |
| Alcon Vision LLC | $3,098.21 | 2019-2025 | Clareon, Clareon Panoptix Pro, Hydrus Microstent |
| Astellas Pharma US INC | $1,873.35 | 2023-2025 | Izervay |
| Abbvie INC. | $1,256.01 | 2022-2025 | |
| Bausch & Lomb Americas INC. | $1,058.37 | 2022-2025 | Vyzulta, Miebo, Xiidra |
| Aerie Pharmaceuticals, INC. | $1,026.05 | 2019-2021 | |
| Glaukos Corporation | $939.82 | 2019-2025 | Idosetr, Idose |
| Ocular Therapeutix, INC. | $747.55 | 2019-2025 | Dextenza |
| Genentech USA, INC. | $710.83 | 2019-2025 | Vabysmo |
| Johnson & Johnson Surgical Vision, INC. | $695.18 | 2019-2025 | Tecnis Simplicity |
| Sight Sciences, INC. | $650.98 | 2019-2025 | Omni Surgical System, Sion Surgical Instrument |
| Novartis Pharmaceuticals Corporation | $529.22 | 2019-2023 | |
| Sun Pharmaceutical Industries INC. | $506.59 | 2019-2023 | Cequa |
| Tarsus Pharmaceuticals, INC. | $463.16 | 2024-2025 | Xdemvy |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $417.58 | 2019-2021 |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alimera Sciences, INC. | $378.06 | 2019-2022 | |
| Mallinckrodt Hospital Products INC. | $359.53 | 2022-2024 | Acthar |
| Allergan, INC. | $261.21 | 2019-2022 | |
| Oyster Point Pharma, INC. | $248.19 | 2022-2024 | Tyrvaya, Ryzumvi |
| Biotissue Holdings INC. | $188.69 | 2019-2025 | |
| Dompe US, INC. | $177.47 | 2021-2025 | Oxervate |
| Horizon Therapeutics Plc | $170.72 | 2022-2023 | Tepezza |
| Kala Pharmaceuticals, INC. | $164.01 | 2019-2021 | |
| Harrow Eye, LLC | $153.80 | 2023-2024 | Vevye, Iheezo |
| Shire North American Group INC | $139.83 | 2019 | |
| Spark Therapeutics, INC. | $130.27 | 2019-2022 | |
| Apellis Pharmaceuticals, INC. | $129.64 | 2022-2025 | Syfovre |
| Ani Pharmaceuticals, INC. | $124.03 | 2023-2025 | Iluvien, Yutiq, Purified Cortrophin Gel |
| Sandoz INC. | $78.82 | 2024 | Cimerli |
| Thea Pharma INC. | $55.10 | 2023 | Iyuzeh |
| Amgen INC. | $54.61 | 2025 | Uplizna |
| Mallinckrodt Enterprises LLC | $42.19 | 2019 | |
| Coherus Oncology, INC. | $40.83 | 2022-2023 | |
| Leadiant Biosciences, INC. | $39.09 | 2020-2022 | |
| Eyepoint US, INC. | $36.95 | 2019-2020 | |
| Rayner Intraocular Lenses Limited | $30.22 | 2022-2024 | Omidria, Rayone Spheric, Rayone Emv |
| Biogen, INC. | $28.12 | 2022 | |
| Halozyme INC | $26.57 | 2025 | Hylenex Recombinant |
| Alexion Pharmaceuticals, INC. | $20.94 | 2020 | |
| New World Medical,INC. | $20.62 | 2023 | |
| Beaver-Visitec International, INC. | $16.82 | 2023 | |
| Omeros Corporation | $16.40 | 2020 | |
| Eyevance Pharmaceuticals LLC | $13.80 | 2023 | Flarex |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Perlmutter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.